CalciMedica (NASDAQ:CALC) Issues Quarterly Earnings Results, Beats Estimates By $1.03 EPS

CalciMedica (NASDAQ:CALC) released its earnings results on Tuesday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.03, FiscalAI reports.

CalciMedica Trading Down 3.2%

NASDAQ:CALC traded down $0.05 during mid-day trading on Tuesday, reaching $1.47. 1,436 shares of the company’s stock traded hands, compared to its average volume of 175,516. The company has a 50 day moving average price of $1.60 and a 200-day moving average price of $3.50. The firm has a market capitalization of $10.01 million, a price-to-earnings ratio of -0.22 and a beta of 0.84. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. CalciMedica has a 12-month low of $1.00 and a 12-month high of $36.00.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CALC. Guggenheim started coverage on CalciMedica in a research report on Thursday, August 20th. They issued a “buy” rating for the company. Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $50.00.

About CalciMedica

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.